BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, November 30, 2024
Breaking News: Healing a health divide (that’s long overdue)
See today's BioWorld Science
Home
» Benevolentai and Merck KGaA enter drug discovery and development collaboration
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Drug Design, Drug Delivery & Technologies
Benevolentai and Merck KGaA enter drug discovery and development collaboration
Sep. 20, 2023
No Comments
Benevolentai Ltd. has signed a strategic collaboration with Merck KGaA to identify novel drug candidates, initially for three targets in oncology, neurology and immunology.
BioWorld Science
Artificial intelligence
Drug design, drug delivery and technologies
Collaboration
Cancer
Immune
Neurology/psychiatric
